{"id":"NCT02770807","sponsor":"Quince Therapeutics S.p.A.","briefTitle":"Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients","officialTitle":"Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients With Ataxia Telangiectasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-02","primaryCompletion":"2021-05-13","completion":"2021-05-13","firstPosted":"2016-05-12","resultsPosted":"2024-05-09","lastUpdate":"2024-05-10"},"enrollment":176,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Nervous System Disease","Genetic Syndrome"],"interventions":[{"type":"DRUG","name":"EryDex Low dose DSP","otherNames":["EryDex System end product"]},{"type":"DRUG","name":"EryDex High dose DSP","otherNames":["EryDex System end product"]},{"type":"DRUG","name":"Pooled Placebo","otherNames":["Placebo EDS infusion"]}],"arms":[{"label":"EryDex Low Dose DSP","type":"EXPERIMENTAL"},{"label":"EryDex High Dose DSP","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Objectives:\n\nThe objective of study was to evaluate the safety and the efficacy of EryDex (Dexamethasone sodium phosphate encapsulated in autologous erythrocytes, using the EryDex System - EDS) at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on Neurological Symptoms in Patients With Ataxia Telangiectasia.\n\nInitial Double-Blind Treatment Period (0 to 6 Months)\n\nPrimary Efficacy Objective:\n\n• Evaluate the effect of EryDex at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on central nervous system (CNS) symptoms measured by the change in the Modified International Cooperative Ataxia Rating Scale (mICARS) from baseline to Month 6 (Visit 9) in patients with ataxia telangiectasia (A-T).\n\nSecondary Efficacy Objectives:\n\n* Evaluate the effect of EryDex, compared to placebo, on the Clinical Global Impression of Change (CGI-C) in patients with A-T from baseline to Month 6 (Visit 9).\n* Evaluate the effect of EryDex, compared to placebo, on measures of Clinical Global Impression of Severity (CGI-S; structured) in patients with A-T from baseline to Month 6 (Visit 9)\n* Evaluate the effect of EryDex, compared to placebo, on measures of Adaptive behavior measures in patients with A-T by the Vineland Adaptive Behavior Scales (VABS) from baseline to Month 6 (Visit 9).\n\nSafety Objectives:\n\n• Evaluate the safety and tolerability of two non-overlapping doses of EryDex, compared to placebo, in patients with A-T over the 12-month double-blind study duration.\n\nExtension Treatment Period (6-12 Months):\n\nPrimary Objective:\n\n• Evaluate the efficacy of EryDex at two dose levels (low dose and high dose DSP/infusion) compared to placebo, in treating CNS symptoms in A-T patients during longer-term treatment (up to 12 months), as measured by the mICARS.\n\nSecondary Objectives:\n\n* Evaluate the longer-term (up to 12 months) safety and tolerability of EryDex in A-T patients.\n* Compare the effects of EryDex on the CGI-C and CGI-S (structured), VABS, and QoL using the EQ-5D-5L scale.","primaryOutcome":{"measure":"Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)","timeFrame":"to Month 6 (Visit 9)","effectByArm":[{"arm":"EryDex Low Dose DSP - mITT","deltaMin":0.8,"sd":3.56},{"arm":"EryDex High Dose DSP - mITT","deltaMin":1,"sd":3.32},{"arm":"Placebo - mITT","deltaMin":2.3,"sd":5.03}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0847"},{"comp":"OG001 vs OG002","p":"0.0765"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":22,"countries":["United States","Australia","Belgium","Germany","India","Israel","Italy","Norway","Poland","Spain","Tunisia","United Kingdom"]},"refs":{"pmids":["39917433","39152028"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":59},"commonTop":["Pyrexia","Cough","Vomiting","Bacterial test positive","Nasopharyngitis"]}}